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Abstract  
Historically, Parkinson’s disease (PD) was viewed as a motor disorder and it is only in recent 
years that the spectrum of non-motor disorders associated with the condition has been fully 
recognized. There is a broad scope of neuropsychiatric manifestations, including depression, 
anxiety, apathy, psychosis and cognitive impairment. Patients are more predisposed to 
delirium and PD treatments give rise to specific syndromes including impulse control 
disorders, dopamine agonist withdrawal syndrome and dopamine dysregulation syndrome. 
This article seeks to give a broad overview of the spectrum of these conditions, describe the 
association with PD disease severity and degree to which dopaminergic degeneration and / 
or treatment influences symptoms. We highlight useful assessment scales that inform 
diagnosis and the current treatment strategies can be employed to ameliorate these 
troublesome symptoms that frequently negatively affect quality of life for people with PD.    
 
Introduction 
Idiopathic Parkinson’s disease (PD), is the second most common neurodegenerative 
disorder after Alzheimer’s disease. Motorically it is characterized by tremor, rigidity, 
bradykinesia, and postural instability. Whilst it was historically considered to be a 
movement disorder, the motor symptoms are now increasingly recognised as representing 
the ‘tip of the iceberg’. The significant underlying burden of non-motor symptoms span 
neuropsychiatric, sleep, somatosensory and autonomic domains.  These can  often precede 
the motor symptoms by years or even decades (Klingelhoefer, 2015) and have a negative 
effect on quality of life.  
 
Parkinson’s has been described as the “quintessential neuropsychiatric disorder” 
(Weintraub, 2011) which reflects both the scope and commonality of neuropsychiatric 
symptoms (illustrated in Figure 1) that can be encountered. Whilst these symptoms are 
common and frequently debilitating, they are under-recognised and invariably have a 




2019). The presence of neuropsychiatric symptoms are associated with overall higher carer 
burden and, potentially, higher care costs whilst being frequently undeclared by patients 
(Chaudhuri, 2006; Politis, 2010). 
 
 
Figure 1: The spectrum of neuropsychiatric disorders in Parkinson’s disease. Treatment-related syndromes are 
indicated in bold text.  
 
In this article we describe the spectrum of neuropsychiatric symptoms that are encountered 
in Parkinson’s necessarily limiting the scope to cover manifestations in idiopathic 
Parkinson’s disease rather than the full spectrum of Parkinsonian syndromes. We describe 
where the underlying aetiology is understood to result from alpha synuclein pathology and 
disruption of neurochemical pathways or where adverse effects of treatments can 
precipitate other manifestations such as impulse control disorders and psychosis. Where 
assessment scales can be usefully utilized to aid diagnosis and assessment of symptom 
severity these are included along with the relative strengths and limitations. Whilst a strong 




in the field is growing year on year (Figure 2). We have sought to provide a pragmatic 
approach to managing neuropsychiatric issues to tackle the unmet need for better 
recognition and treatment of these often under-recognised and frequently inadequately 
managed symptoms.  
 
Figure 2: Number of articles published in each neuropsychiatric domain between 1961 and 2018. The PubMed 
search terms used were: cognition = Parkinson* AND (dementia OR cognitive impairment); depression = Par-
kinson* AND depression; psychosis = Parkinson* AND (psychosis OR hallucination); impulse control disorders 
(ICDs) = Parkinson* AND (impulse control disorder OR dopamine dysregulation syndrome); anxiety = Parkin-
son* AND anxiety; apathy = Parkinson* AND apathy; sleep and wakefulness = Parkinson* AND (insomnia OR 




In his original essay on The Shaking Palsy, James Parkinson noted that “A more melancholy 
object I never beheld” (Parkinson, 1817). Nowadays, depression is still recognised as a 
common non-motor feature of PD, with the prevalence of clinically significant symptoms 
being 35% (Reijnders, 2008). A multi-centre study demonstrated that half the study patients 
were depressed according to the Beck Depression Inventory whilst only 1% had self-
reporting symptoms (Findley, 2002; Huse, 2005). There are particular diagnostic challenges 




2011), hypomimia (lack of facial expression), concurrent mood disturbances such as anxiety 
or apathy (Pagonabarraga, 2015a), psychomotor slowing, as well as under recognition by 
clinicians (Shulman, 2002). There are a number of validated screening tools available which 
may be utilized to identify depression in people with PD including the Hamilton Depression 
Rating Scale (HAM-D), Beck Depression Inventory (BDI), Hospital Anxiety and Depression 
Scale (HADS), Montgomery Asberg Depression Rating Scale (MADRS), and the Geriatric 
Depression Scale (GDS) all of which are recommended by the International Parkinson and 
Movement Disorder Society. A working group on depression in Parkinson’s recommended 
that an inclusive approach be taken to symptoms (i.e. regardless of the aetiology) and that 
motoric ‘on’ or ‘off’ state should be considered when making a diagnosis (Marsh, 2006).  
 
The underlying pathophysiology of depression in PD is poorly understood and likely to be 
multifactorial. A study of almost fifteen hundred patients concluded that higher rates of 
depression were seen in patients with increasing severity of motor symptoms (Riedel, 
2010). Whilst there may be a reactive element to living with a neurodegenerative condition, 
there is substantial evidence of a neurotransmitter deficit. This biochemical basis is likely 
mediated through alteration in serotonin, noradrenaline, and acetylcholine. These changes 
may have a cumulative effect with the hypodopaminergic state with depressive symptoms 
being more prominent in the motorically ‘off’ state (van der Velden, 2018). Pharmacological 
trials have demonstrated an anti-depressant effect with the dopamine agonists pramipexole 
and ropinirole (Barone, 2010). 
 
The choice of pharmacological therapy is often driven by determination of symptom 
severity and effect on a patient’s quality of life. The options in treating depression in PD are 
similar to that of depression in any chronic disease state and include selective serotonin 
reuptake inhibitors (SSRIs), serotonin norepinephrine uptake inhibitors (SNRI), mono-amine 
oxidase type B inhibitors (MAOBI), and tricyclic antidepressants (TCA). However, there is a 
paucity of robust randomised controlled trial evidence. SSRIs are most commonly prescribed 
because of their more favourable side effect profile and lower potential for drug-drug and 
drug-disease interactions. The use of MOABIs for the motor treatment of PD increases the 
risk of developing serotonin syndrome through the addition of an antidepressant, although 




advantage in promoting sleep in patients who suffer insomnia, the anticholinergic effects of 
this drug class and daytime somnolence should be considered. Treatment approaches to 
depression in PD should ideally be delivered within the framework of a multidisciplinary 





Apathy is one of the most common non-motor features of PD (den Brok, 2015). Increasing 
efforts have been made within the last decade to distinguish apathy as an isolated mood 
disorder from apathy as a ‘by-product’ of depression, although the two symptoms 
frequently coexist (den Brok, 2015). Apathy may be defined as a “state of reduced 
motivation with decreased goal-directed behaviours”(Marin, 1991). This may result in low 
levels of activity, reduced interests and a loss of socialization. The overlap in symptoms 
between apathy and depression can make diagnosing isolated apathy challenging. There 
are, however, certain characteristic thoughts and symptoms that are specific to apathy and 
the presence or absence of these help to confirm the diagnosis. These include emotional 
indifference and reactivity, reduced activity and interest in the world with a lack of concern 
for others (Pagonabarraga, 2015b). Depending on the diagnostic criteria used, and the 
concurrent symptoms of depression and cognitive impairment, the prevalence of apathy 
ranges from 17-70% in PD (Aarsland, 2009) and, similarly to depression, the symptoms may 
precede the motor symptoms of PD. The pathophysiology is poorly understood, but may be 
associated with a neuronal disruption in areas that regulate goal-directed behaviour; mainly 
dopaminergic projections between the frontal cortex and the ventral tegmentum (Marin, 
1991; Carlson, 2011). 
 
The development of diagnostic criteria for apathy has advanced significantly with the 
development of a task force, commissioned in 2008 by the International Parkinson’s and 
Movement Disorder Society, to assess the clinimetrics of the available rating scales 
(Shulman, 2016). Subsequent review of the clinimetric properties of 13 scales suggested 
that the five item WHO Well-being Index (WHO-5) and Neurasthenia Scale detect apathy 




while the Starkstein Apathy Scale (SAS) has utility in the exclusion of apathy (Carrozzino, 
2019). 
 
There are a range of therapeutic approaches to treating apathy including dopaminergic 
medications (Marsh, 2006; Chaudhuri, 2013). A double-blind randomized controlled trial 
comparing the cholinesterase inhibitor rivastigmine with placebo showed a significant 




It is estimated that a third of people with PD experience symptoms of anxiety, which is 
considered to be a group of disorders consisting of generalized anxiety disorder (GAD), 
obsessive compulsive disorder, agoraphobia, social phobia, and panic disorder. It can be 
difficult to distinguish symptoms of anxiety from those of depression or even somatic PD 
(e.g. sleep disturbances, apathy), which can also be present simultaneously; so, the 
identification of one should lower the threshold of clinical suspicion for the other.  
 
Classification of these conditions vary in studies, therefore the reported prevalence rates 
vary, ranging from 3.6% to 55% (Dissanayaka, 2010; Broen, 2016). A systematic review 
reported the average prevalence of all anxiety disorders in PD to be 31%, with GAD, panic 
disorder, and social phobia being the most common (Broen, 2016). This wide difference in 
prevalence may be accounted for by the underreporting of symptoms by patients and under 
recognition by clinicians. 
 
Researchers will often rely on established criteria, for example from the DSM 4, to make a 
diagnosis; however, diagnosis in a clinical setting can remain challenging. a study of 42 
patients with Parkinson’s disease in a university-based movement disorders clinic found that 
29% had DSM-III-R anxiety disorder diagnoses, but an additional 40% had anxiety symptoms 
that did not meet the diagnostic threshold (cited in The DSM-IV criteria can be useful to aid 
diagnosis but people with anxiety and PD will not invariably meet these criteria. For 
example, in a university‐based movement disorders clinic (n = 42), 29% of subjects with PD 




an additional 40% had anxiety symptoms that did not meet criteria for a DSM diagnosis 
(Pontone, 2009). Confirmation of the diagnosis can be challenging because of the overlap 
between somatic features such as sleep disturbance. Self-reported anxiety scales have been 
tested in PD, but their clinical utility is uncertain owing to the lack of consensus regarding 
appropriate cut-off scores (Leentjens, 2008). A detailed patient history and a collateral 
history are essential but often omitted because of time constraints in clinic. Furthermore, 
identification can be complicated by the presence of an underlying cognitive impairment. 
Specific symptoms of anxiety in PD include panic attacks during off periods, excessive worry, 
and increased subjective motor symptoms. The timing of symptoms can mirror motor 
fluctuations or manifest in an unrelated pattern (Aarsland, 2009). 
 
Similarly to depression in PD, the aetiology of anxiety is multifactorial. There may well be 
underlying neurobiological changes that cause anxiety; but so, too, it is likely that there are 
psychosocial causes in reaction to the burden of having PD. Social anxiety is especially 
common in the context of the reactive model, with people with PD  expressing concern over 
being negatively perceived in public leading to social withdrawal. Patients may also fear the 
progression of the disease, disability, institutionalization, and issues surrounding their 
death. With the high falls risk in the disease, an associated fear of falling can be very 
prominent (Prediger, 2012). 
 
The role of dopaminergic neurotransmission in the context of anxiety is poorly understood 
but has been linked to both social phobia and anxiety symptoms in animal models (Prediger, 
2012). Serotonergic and noradrenergic systems also have a role in PD anxiety owing to their 
widespread distribution in the structures involved in emotional modulation. Research 
demonstrates that people with PD who score higher on anxiety questionnaires have a 
shorter serotonin transporter allele, highlighting the potential role of neuropsychiatric 
genetics in this group (Menza, 1990). 
 
Anxiety in PD has a huge impact on quality of life, not only for the patient but also for their 
family and carers. Social anxiety can lead to isolation in the community that further 
exacerbates anxiety creating a self-perpetuating cycle. It can also precipitate loneliness, 




depression. This can in turn affect treatment plans, hindering motivation and engagement in 
rehabilitation and healthcare services (Prediger, 2012). 
 
There is a paucity of evidence on the management of anxiety in PD. There are no robust 
clinical trials of either pharmacological or psychological strategies. Anxiety has been 
assessed as a secondary outcome in depression clinical trials but because of the selection 
criteria used, any therapeutic effects on anxiety were diluted (Koychev, 2017). 
Guidance for managing anxiety in older adults with chronic physical health conditions 
(Koychev, 2017) can be extrapolated, which places initial emphasis on lifestyle modification, 
focussing on optimal sleep, exercise, nutrition, and socializing in addition to eliminating any 
exacerbating medical causes for anxiety such as metabolic anomalies, nutritional 
deficiencies, and drug reactions. Pharmacological approaches are then advised with the 
introduction of SSRIs and SNRIs. The use of benzodiazepines is discouraged because of their 
side effect profile. Behavioural therapies in the form of cognitive behavioural therapy, 
mindfulness, and desensitization are also of benefit but are reliant on adequate motivation 




Psychosis in PD is a spectrum of neuropsychiatric manifestations consisting of ‘positive’ 
symptoms namely illusions, hallucinations, and delusions (Ravina, 2007). Definitions of 
psychotic symptoms in the context of PD are consistent with the definitions in the wider 
psychiatric literature. The prevalence of psychosis also varies depending on the diagnostic 
tool used. In 2007, the combined National Institute of Neurological Disorders and Stroke 
(NINDS) and National Institute of Mental Health (NIMH) work group proposed a unifying 
diagnostic criterion for PD psychosis which includes the presence of at least one psychotic 
symptom (Ravina, 2007). Longitudinally, prevalence increases with disease duration, 
(Gibson, 2013) and at 12 years 60% of patients from a community cohort reported 
hallucinations or delusions (Forsaa, 2010). 
 
Proposed risk factors for the development of psychosis in PD includes duration and severity 




demands associated with caring for the people with PD are already high results in a greater 
sense of burden for the carer in comparison with caring for those without psychosis and is 
also a predictive factor for nursing home placement (Marsh, 2004). Additional risk factors 
for psychosis include treatment with dopaminergic and anti-cholinergic medications. The 
relationship between the use of PD medication and development of PD psychosis remains 
controversial. Anecdotally, an association between PD psychosis and the use of 
dopaminergic therapies and duration of treatment has been observed. Psychotic symptoms 
can develop on initiation of medication with a subsequent improvement with reduction or 
withdrawal and this is most potently seen with the use of dopamine agonists. None the less, 
a causal effect of dopaminergic medications has not been established and psychotic 
symptoms have been described in recently diagnosed patients who have not yet started 
treatment (Aarsland, 2009).   
 
The initial management of PD psychosis involves the identification and treatment of any 
precipitating factors. Psychosis may be the manifestation of an acute illness or change in 
medication and a thorough clinical evaluation is imperative. If the patient is tolerating the 
symptoms of psychosis with no adverse features, the best approach may be to watch and 
wait. Many patients with PD do not find hallucinations distressing and retain insight.  
Where intervention is warranted, there are a number of approaches. In patients with 
significant cognitive impairment, rivastigmine has good efficacy (Burn, 2006). Clozapine and 
pimavanserin (a 5-HT2A inverse agonist, not yet licensed for use in the UK) are efficacious  
(Cummings, 2014). There are barriers for the routine use of clozapine in the clinical setting, 
namely the regular blood tests required to monitor for agranulocytosis and the registration 
required for prescribing the drug. Other atypical antipsychotics used in clinical practice 
include quetiapine, olanzapine, and risperidone, but these can cause worsening of motor 
symptoms and other side effects including QT prolongation, sedative effects, metabolic 
syndrome, and a potential deterioration in cognition. The most recent National Institute for 
Health and Care Excellence (NICE) advocates the use of low-dose quetiapine and clozapine 
as the most appropriate medications in PD psychosis,(National Institute for Health and Care 
Excellence, 2017) and in clinical practice at present, quetiapine is commonly used. 






Cognitive impairment is a common non-motor manifestation in PD and is heterogeneous in 
terms of its severity, rate of progression, and the cognitive domains affected. It has a 
significant negative impact on patients and their carers and is associated with increased 
disability, mortality (Levy, 2002), carer burden, (Aarsland, 1999) and need for nursing home 
placement (Aarsland, 2000). Although Lewy body dementia (LBD) is beyond the scope of this 
article, it is important to mention that both PD dementia (PDD) and LBD share many clinical 
and neurochemical features despite being two distinct entities. Their diagnosis is based on 
an arbitrary distinction between the time of onset of dementia in relation to motor 
symptom onset. In PDD, cognitive impairment presents one or more years after the 
presentation of parkinsonism, whereas in LBD, cognitive impairment often precedes 
parkinsonism (Aarsland, 2016).  In idiopathic PD, cognitive impairment ranges from 
subjective cognitive decline, to mild cognitive impairment (MCI), to dementia, but does not 
necessarily progress linearly.  
 
Longitudinal studies suggest MCI in PD increases the risk of developing Parkinson’s disease 
dementia (PDD). Janvin et al., showed, whilst controlling for age, disease stage, education, 
and gender, that MCI was strongly associated with PDD development (odds ratio 5.1; 95% 
CI, 1.51 to 16.24, p= 0.005) over a four-year follow up (Janvin, 2006). However, this study 
included relatively small numbers. More recently, evidence suggests MCI may not always 
progress to PDD, with some patients remaining stable on longitudinal assessments or even 
reverting back to normal cognition (Lawson, 2017). The prevalence of MCI in PD ranges from 
15-53% (Yarnall, 2013) but this large variation in prevalence is likely caused by differences in 
study settings (hospital versus community patients), variable clinical characteristics, and 
inconsistent definitions of MCI in PD. The Movement Disorders Society published a unifying 
set of diagnostic measures in 2012 to standardize practice across clinical trials (Litvan, 
2011). From a clinical perspective, MCI and PDD can be best differentiated by determining 
whether the cognitive impairment significantly impacts activities of daily living.   
 
Several longitudinal studies have demonstrated that approximately 50% of patients develop 




Multicenter Study, the largest follow-up study of newly diagnosed patients, showed 83% of 
patients with PD developed PDD at 20 years post diagnosis and 75% developed PDD before 
death (Hely, 2008). Additionally, not only does the progression of cognitive impairment in 
PD vary, so too does the pattern of cognitive deficits. Cognitive deficits may affect executive 
function, attention, processing speed and/or visuospatial function (Williams-Gray, 2007). 
The CamPaIGN (Cambridgeshire Parkinson’s Incidence from GP to Neurologist) cohort study 
assessed cognition at 3.5 and 5.5 years post diagnosis and found a decline in MMSE (mini-
mental state examination) score at a rate of 0.3±0.1 points per year over 5.2 years 
(Williams-Gray, 2009). In addition, they showed that deficits in semantic fluency and 
visuospatial function at baseline were associated with a greater risk for developing PDD 
whereas deficits in executive function were not (Williams-Gray, 2007, 2009). This finding, in 
addition to other studies, led to the “dual syndrome hypothesis” which suggests that 
patients with primarily executive dysfunction, driven by changes in dopaminergic pathways, 
are less likely to develop PDD, whereas those with memory and visuospatial functional 
deficits, caused predominantly by deficits in acetylcholine, are more prone to rapid 
cognitive decline and progression to PDD. 
 
The heterogeneity of both the presentation and progression of cognitive impairment in PD 
is not fully understood and is clearly a complex interplay between genetic and 
environmental factors. Risk factors associated with an increased risk for PDD include patient 
age, older age of disease onset, and the presence of hallucinations. In addition, the 
Parkinson’s phenotype with more predominant gait dysfunction are associated with a more 
rapid cognitive decline than those with a tremor dominant phenotype (Williams-Gray, 
2009). Genetic factors also play a role with mutations in the alpha-synuclein gene (SCNA) 
mutation (Waxman, 2009) and glucocerebrosidase (GBA -1) gene (Cilia, 2016) being 
associated with a more rapid cognitive decline, in addition to an earlier onset of PDD. One 
retrospective longitudinal study found that that 56% of GBA1 mutation carriers had 
dementia at age 70, compared with 15% of sporadic PD patients (Cilia, 2016). Interestingly, 
patients with a PARKIN mutation, which accounts for 50% of autosomal recessive PD, are 
less likely to develop PDD, with one review finding PDD in fewer than 3% of cases 





The only drug currently licensed for PDD is rivastigmine, an acetyl cholinesterase inhibitor, 
with Memantine, an N-methyl-D-Aspartate (NMDA) receptor antagonist used as second line 
if the patient is intolerant to Rivastigmine (National Institute for Health and Care Excellence, 
2017). However, a meta-analysis including three randomized controlled trials comparing 
memantine 20mg daily to placebo concluded it only had a mildly beneficial effect on the 
global impression of change assessment, with no significant change on cognitive function 
assessed using the MMSE (Wang, 2015). There is currently no successful treatment for MCI, 
and given the limited pharmacological options, it is important to consider non-
pharmacological options including physical exercise programmes, cognitive training and 
stimulation using pharmacological and non-pharmacological approaches. 
  
A systematic review of eight studies including 158 patients suggested that physical exercise 
had beneficial effects on global cognition, in particular on executive function, as assessed 
using the MoCA scale (Cruise, 2011; Murray, 2014). Physical activity intervention studies 
have historically recruited small numbers of patients and utilized heterogeneous 
interventions with varying degrees of exercise intensity, mode and duration.  
Cognitive training is a structured teaching programme designed to target specific cognitive 
domains. A meta-analysis involving seven studies (n=272 patients) showed a small but 
statistically significant improvement compared with controls (Leung, 2015). Overall, given 
the heterogeneity of cognitive impairment in PD and the impact it has on the patient’s 
quality of life and carer burden, the primary aim of management should be to apply an 




Given the propensity to develop dementia and the high degree of cognitive vulnerability it is 
proposed that people with PD are at increased risk of developing delirium in the setting of 
acute illness (Vardy, 2015). The features of delirium such as cognitive fluctuation, 
somnolence, and hallucinations can overlap with those seen particularly in PDD which can 
confound the diagnosis. There is a lack of evidence as to the long-term motor and cognitive 
outcomes for people with PD who have experienced delirium although there is a suggestion 




2005; Umemura, 2014). Whilst antipsychotics can worsen motor symptoms, clinically 
quetiapine is most commonly used where pharmacological strategies are required in 
addition to treating any underlying precipitants and using conservative strategies such as 
one-to-one nursing and environmental optimisation.   
 
Treatment related disorders  
 
Impulse control disorders  
Impulse control disorders (ICDs) are addictive behaviours manifesting as binge eating, 
pathological gambling, compulsive shopping, or abnormal sexual behaviours (Weintraub, 
2010). These can occur in isolation or together. In Parkinson’s disease they are associated 
with dopamine agonist therapy, and all patients initiated on this treatment should be 
counselled as to the risk and proactive enquiry at subsequent appointments should be used 
to ascertain whether these symptoms are arising. Left unrecognized and untreated, ICDs can 
have very significant ramifications on personal relationships and finances. Individuals at 
higher risk of developing ICDs are men, those with certain personality traits or psychiatric  
disturbance (such as impulsivity, novelty-seeking, anxiety, and depression), younger 
patients, smokers, and those taking higher doses of DA (dopamine agonists) for a longer 
duration. Management consists of down-titration of DA therapy supported by cognitive 
behavioural therapy with careful management of worsening motor symptoms (Okai, 2013). 
 
Dopamine agonist withdrawal (DAWS)  
Dopamine agonist withdrawal results from the rapid down titration or withdrawal of a 
dopamine agonist drug. Clinically is recognized by a cluster of symptoms including 
autonomic instability (fatigue, orthostatic hypotension, nausea, vomiting, diaphoresis), 
psychological symptoms (anxiety, panic attacks, dysphoria, depression, fatigue, agitation, 
irritability, suicidal ideation) as well as generalised pain, and drug cravings (Nirenberg, 
2013). [67] The cessation or rapid reduction of dopamine agonist drugs is a major factor in 






Dopamine dysregulation syndrome (DDS)  
Dopamine dysregulation syndrome refers to the compulsive (mis)use of dopaminergic 
therapy. The combination of dopamine replacement therapy, coupled with predisposing 
individual risk factors and PD pathology, yielding an addictive syndrome (Béreau, 2018). This 
manifests as mood fluctuations and addictive behaviour. Management consists of careful 
down titration of dopamine agonist therapy and fractionation of levodopa therapy. 
Intrajejunal levodopa infusion therapy or deep brain stimulation can be considered in 




Neuropsychiatric manifestations of PD are common and have a devastating effect on 
patients’ quality of life and cause significant carer strain. Assessment and active 
management of the neuropsychiatric symptoms encountered in people with PD is essential 
to mitigate these very distressing sequelae and the resultant negative impact these 
conditions can have on functioning. The overlap of symptoms can make the diagnosis of a 
mental health disorder in the context of PD challenging, but proactive enquiry is the first 
step in better defining and treating these syndromes. In this brief review we have sought to 
give an overview of the spectrum of conditions, current understanding of pathophysiology, 
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• By the end of the manuscript the reader will  
• understand the scope of the potential psychiatric manifestations of Parkinson’s disease, 
including those which may be caused by or precipitated by treatments.  
• recognise assessment scales that are available to aid diagnoses of neuropsychiatric 
conditions. 
• Have  insight into some of the current treatments for the mental health problems that are 









Select the single best answer for each question stem 
 
 
1. When considering depression in Parkinson’s disease: 
 
a) there is no relationship between rates of depression and severity of motor symptoms  
b) Validated screening tools include Hospital Apathy and Depression scale (HADS), Starkstein 
Apathy Scale (SAS) and Geriatric Depression Scale (GDS) 
c) Motor “on” or “off” state should be considered when making a diagnosis of depression 
d) Dopamine Agonists should be avoided in patients with depression 
e) Serotonin syndrome is commonly clinically encountered in patients with PD depression  
 
2.  Impulse control disorders are most commonly associated with: 
 
a) Levodopa 
b) Dopamine agonists 
c) Monoamine oxidase inhibitors 
d) Catechol-O-methyltransferase (COMT) inhibitors  
e) Deep brain stimulation  
 
3. With regards to Anxiety: 
a) Obsessive compulsive disorder is the commonest disorder seen in patients with PD 
b) There are no gold standard diagnostic criteria  
c) A longer serotonin transporter allele is associated with higher levels of anxiety in PD 
d) Medical causes should be excluded before diagnosing an anxiety disorder 
e) Benzodiazepines are the first line in treatment of anxiety in PD 
 
4. Patients with PD: 
 
a) are more likely to develop rapid cognitive decline if they are of tremor-dominant phenotype  
b) are more likely to develop PD dementia if they possess the PARKIN mutation 




d) Are unlikely to benefit from physical therapy with regards to their cognition 
e) Who have visuospatial dysfunction, are more likely to develop PD dementia 
 
5.  With regards to psychosis in PD: 
 
a) Psychosis exclusively presents late in the course of PD  
b) Quetiapine and risperidone do not affect motor symptoms 
c) Prevalence increases with disease duration 
d) Treatment of psychotic symptoms should be initiated regardless of the impact the symptoms are 
having on the patient.  
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